Willingness to Be Vaccinated against COVID-19 in Spain before the Start of Vaccination: A Cross-Sectional Study

Vaccine hesitancy has increased in the past few years, influenced by the socio-cultural differences, political populism, or concerns related to the effectiveness and safety of some vaccines, resulting a feeling of distrust. This feeling can become a barrier against the achievement of the immunity necessary to stop the expansion of COVID-19. The aim of this study was to evaluate the acceptance of the vaccine against COVID-19 in Spain, as well as to identify the factors that have an influence on the concerns and attitudes of people against accepting the vaccine in the months prior to the start of vaccination on December 2020. An online questionnaire was created to obtain information about (1) sociodemographic characteristics; (2) concerns and sources of information about vaccines; and (3) attitudes about vaccination and state of health. A multivariate logistic regression was performed to identify the influencing factors. Of the 2501 participants, 1207 (48.3%) would accept the COVID-19 vaccine, 623 (24.9%) were hesitant, and 671 (26.8%) would reject it. The logistic regression showed that being male, older than 60, married, retired, with a high level of education, or with a leftist political inclination, could increase the probability of accepting the COVID-19 vaccine. Disinformation and the lack of political consensus were the main sources of distrust. The patients with hypertension, immunodepression, hypercholesterolemia, or respiratory disease, or were overweight, showed a greater acceptance to the vaccine, while those with cancer took the longest to accept it. A low acceptance of the vaccine against COVID-19 was observed among the Spanish population in the phase prior to its availability, and the main fears of the population were identified. It is necessary to offer correct and transparent information about these vaccines to reduce the concerns and increase the trust of the population, to thereby guarantee the success of the vaccination campaigns

Passive design strategies and performance of Net Energy Plus Houses

The first step in order to comply with the European Union goals of Near to Zero Energy Buildings is to reduce the energy consumption in buildings. Most of the building consumption is related to the use of active systems to maintain the interior comfort. Passive design strategies contribute to improve the interior comfort conditions, increasing the energy efficiency in buildings and reducing their energy consumption. In this work, an analysis of the passive strategies used in Net Energy Plus Houses has been made. The participating houses of the Solar Decathlon Europe 2012 competition were used as case studies. The passive design strategies of these houses were compared with the annual simulations, and the competition monitored data, especially during the Passive Monitored Period. The analysis included the thermal properties of the building envelope, geometric parameters, ratios and others passive solutions such as Thermal Energy Storage systems, evaporative cooling, night ventilation, solar gains and night sky radiation cooling. The results reflect the impact of passive design strategies on the houses' comfort and efficiency, as well as their influence in helping to achieve the Zero Energy Buildings category

Improving Arctic weather and seasonal climate prediction: recommendations for future forecast systems evolution from the European project APPLICATE

The Arctic environment is changing, increasing the vulnerability of local communities and ecosystems, and impacting its socio-economic landscape. In this context, weather and climate prediction systems can be powerful tools to support strategic planning and decision-making at different time horizons. This article presents several success stories from the H2020 project APPLICATE on how to advance Arctic weather and seasonal climate prediction, synthesizing the key lessons learned throughout the project and providing recommendations for future model and forecast system development.The results discussed in this article were supported by the project APPLICATE (727862), funded by the European Union's Horizon 2020 research and innovation programme. PO was additionally supported by the Spanish fellowship RYC-2017-22772.Peer ReviewedArticle signat per 29 autors/es: Pablo Ortega (1), Edward W. Blockley (2), Morten Køltzow (3), François Massonnet (4), Irina Sandu (5), Gunilla Svensson (6), Juan C. Acosta Navarro (1), Gabriele Arduini (5), Lauriane Batté (7), Eric Bazile (7), Matthieu Chevallier (8), Rubén Cruz-García (1), Jonathan J. Day (5), Thierry Fichefet (4), Daniela Flocco (9), Mukesh Gupta (4), Kerstin Hartung (6,10), Ed Hawkins (9), Claudia Hinrichs (11), Linus Magnusson (5), Eduardo Moreno-Chamarro (1), Sergio Pérez-Montero (1), Leandro Ponsoni (4), Tido Semmler (11), Doug Smith (2), Jean Sterlin (4), Michael Tjernström (6), Ilona Välisuo (7,12), and Thomas Jung (11,13) // (1) Barcelona Supercomputing Center, Barcelona, Spain | (2) Met Office, Exeter, UK | (3) Norwegian Meteorological Institute, Oslo, Norway | (4) Université catholique de Louvain, Earth and Life Institute, Georges Lemaître Centre for Earth and Climate Research, Louvain-la-Neuve, Belgium | (5) European Centre for Medium-Range Weather Forecasts, Reading, UK | (6) Department of Meteorology, Stockholm University, Stockholm, Sweden | (7) CNRM, Université de Toulouse, Météo-France, CNRS, Toulouse, France | (8) Météo-France, Toulouse, France | (9) National Centre for Atmospheric Science, Department of Meteorology, University of Reading, Reading, UK. | (10) Now at: Deutsches Zentrum für Luft- und Raumfahrt, Institut für Physik der Atmosphäre, Oberpfaffenhofen, Germany | (11) Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research, Bremerhaven, Germany | (12) Now at: Meteorology Unit, Finnish Meteorological Institute, Helsinki, Finland | (13) Department of Physics and Electrical Engineering, University of Bremen, Bremen, GermanyPostprint (published version

Experiences and methodology in a multidisciplinary energy and architecture competition: Solar Decathlon Europe 2012

Solar Decathlon Europe is an international competition among universities which promotes interdisciplinary learning in engineering and architecture. Students from different disciplines participate in teams guided by several professors during a 29 month preparation period plus five weeks of on-site contest. The educational project involves designing, building and testing a solar energy house connected to the electrical grid with the strategy of maximizing self-consumption, supported by bioclimatic technologies and maintaining a low environmental footprint. It culminates in a on-site contest in which teams must assembly the house themselves, test it with ordinary real life tasks and finally disassembly it. The event has also a divulgative aim, trying to make students and visitors get interested in discovering the problems presented by real engineering and architecture applications. In addition, SDE covers R&D aspects in different fields such as energy efficiency, solar energy and bioclimatic architecture. This article presents the methodology followed during the SDE 2012 edition, in which more than 850 students participated. The obtained results show that the educational competition was a success according to the technical and professional ambitions of the students, most of them considering that their knowledge had increased in areas related to technical and multidisciplinary aspects

Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.This work was supported in part by the Spanish AIDS Research Network (RD16/0025/0017, RD16/0025/0018), which is included in the Spanish I+D+I Plan and is co-funded by the ISCIII-Subdirección General de Evaluación and European Funding for Regional Development (FEDER). The sponsors had no role in the study design, the collection, analysis and interpretation of data, the writing of the report, or the decision to submit the article for publication.S

Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

Background: We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods: The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results: The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions: Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.This work was funded by grant Ref. no. GLD14-00279 from the GILEAD Fellowship Programme (Spain) and by the Spanish AIDS Research Network (RD16/0025/0017, RD16/0025/0018) that is included in the Spanish I+D+I Plan and is co-financed by ISCIII-Subdirección General de Evaluacion and European Funding for Regional Development (FEDER).S

Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

Altres ajuts: Spanish AIDS Research Network; European Funding for Regional Development (FEDER).Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population

Flexible industrial work in the European periphery: factory regimes and changing working class cultures in the Spanish steel industry

This article explores how two steel industry firms operating in northern Spain have adapted to neoliberalism and globalization. Despite their geographical proximity, the comparison between their different trajectories, production, and ownership profiles highlights how their distinct factory regimes, while becoming entangled in global market dynamics, have allowed the emergence of contrasting definitions of workers’ identities, labor politics, and livelihood strategies, raising questions concerning (1) processes of distribution of privileges, skills, and knowledge among the workforce, and (2) the shaping of social relations, values, and meanings that result in the formation of particular factory regimes. The unequal position of steelmaking in regional economies, and the effects of economic policies that framed social relations in each firm, evince important differences between them, including contrasting expressions of resistance, discipline, and sociality on the shop floor. Our comparison considers how particular factory regimes bring forward different prospects as these firms face further industrial transformation, restructuring, and an increasingly uncertain future

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie